Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Biogen Inc. (BIIB) , which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider.This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 7.95%.For the most recent quarter, Biogen Inc. Was e ...

In the latest trading session, Biogen Inc. (BIIB) closed at $251.68, marking a +1.36% move from the previous day. This move outpaced the S&P 500's daily gain of 0.29%. Meanwhile, the Dow experienced a drop of 0.25%, and the technology-dominated Nasdaq saw an increase of 0.43%.Heading into today, shares of the company had lost 3.75% over the past month, lagging the Medical sector's gain of 2.29% and the S&P 500's gain of 2.08% in that time.The upcoming earnings release of Biogen Inc. will be of great interes ...

Sizzling hot. Those two words just might be the best description of the Nasdaq-100 Index in 2023. The tech-heavy index skyrocketed nearly 54%, its best performance so far in the 21st century. But will the Nasdaq-100 keep its momentum going in the new year? Analysts don't seem to think so. Their average 12-month price targets don't point to any stock in the index beating the return that it achieved last year.However, a handful of stocks could nonetheless deliver impressive gains if analysts are right. These ...

Biogen Inc. (BIIB) ended the recent trading session at $255.84, demonstrating a -0.83% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.15% for the day. Meanwhile, the Dow experienced a drop of 0.42%, and the technology-dominated Nasdaq saw an increase of 0.09%.Shares of the company witnessed a gain of 4.82% over the previous month, trailing the performance of the Medical sector with its gain of 6.58% and outperforming the S&P 500's gain of 3.5% ...

Biogen Inc. (NASDAQ:BIIB) J.P. Morgan 42nd Annual Healthcare Conference January 8, 2024 2:15 PM ET Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P. Morgan Chris Schott So good morning, everybody. I'm Chris Schott at JPMorgan, and it is my pleasure to be hosting a fireside chat today with Chris Viehbacher who joined Biogen as CEO, I guess, a little bit over a year ago. So, Chris, Happy New Year. Chris Viehbacher Happy new year to you too, Chris. Chris Schott Yes. ...

Key Pointsbluebird bio has three FDA-approved gene therapy treatments that are planning to commercialize after its $150 million secondary offering of common shares priced at $1.50 per share.bluebird bio's latest FDA approval, LYFGENIA, is a one-time treatment for sickle cell disease, which is priced around $3.1 million per patient, which is 40% higher than Vertex Pharmaceutical's Casgevy at $2.1 million, which was approved on same day Dec. 8, 2023.Sangamo Therapeutics has paused further investment into two ...

Biogen Inc. (BIIB) closed the latest trading day at $263.43, indicating a -1.6% change from the previous session's end. The stock trailed the S&P 500, which registered a daily loss of 0.8%. Meanwhile, the Dow experienced a drop of 0.76%, and the technology-dominated Nasdaq saw a decrease of 1.18%.The company's shares have seen an increase of 16.61% over the last month, surpassing the Medical sector's gain of 5.8% and the S&P 500's gain of 3.4%.The upcoming earnings release of Biogen Inc. will be of great in ...

Alcyone's ThecaFlex DRx™ System is an FDA Breakthrough designated implantable medical device in clinical development to enable routine subcutaneous administration of therapeutics to the cerebrospinal fluid to potentially improve patient experience The first implantation of the ThecaFlex DRx™ System was performed at Texas Children's Hospital in Houston, Texas by PIERRE study investigator David Bauer, MD, MPH LOWELL, Mass., Jan. 3, 2024 /PRNewswire/ -- Alcyone Therapeutics Inc. (Alcyone), a biotechnology co ...

Biogen Inc. (NASDAQ:BIIB) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Well, thank you guys for being here. Pleasure to have Biogen management join us. We're only going to talk about the 10,000 patients by end of March and no other topic. But in all seriousness, thank you Priya for being here. I'll turn it over to you to kick things off. Priya Singhal Sur ...

Biogen Inc. (NASDAQ:BIIB) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chuck Triano - Head of Investor Relations Christopher Viehbacher - President and Chief Executive Officer Priya Singhal - Head of Development Michael McDonnell - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Brian Abrahams - RBC Capital Markets Robyn Karnauskas - Truist Securities Umer Raffat - Evercore ISI Michael Yee - Jefferies T ...